Atossa Therapeutics, Inc. · LSX:A2JJ99

Atossa Therapeutics, Inc. financial statements

Atossa Therapeutics, Inc.'s income statement, balance sheet and cash flow, annual and quarterly, each figure dated and linked to the filing it was read from.

Financials

Annual, in USD

Income statement

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Revenue0000000000
Cost of revenue16.0K17.0K23.0K8.00K23.0K46.6K52.8K44.2K129.0K303.5K
Gross profit-16.0K-17.0K-23.0K-8.00K-23.0K-46.6K-52.8K-44.2K-129.0K-303.5K
Research and development21.2M14.1M17.3M15.1M9.21M6.61M6.65M4.21M2.33M770.4K
Selling, general and administrative16.0M13.5M14.0M12.6M11.3M8.00M10.6M7.22M4.86M6.48M
Operating income-37.1M-27.6M-31.4M-27.7M-20.5M-14.6M-17.3M-11.4M-7.65M-7.97M
Depreciation and amortization16.0K17.0K23.0K8.00K23.0K47.0K52.8K44.2K129.0K303.5K
EBITDA-37.1M-27.6M-31.4M-27.7M-20.5M-14.6M-17.2M-11.4M-7.52M-7.67M
Interest expense8.00K85.0K938.8K00192.8K0
Income before tax-34.8M-25.5M-30.1M-27.0M-20.6M-17.8M-17.2M-11.4M-8.12M-6.37M
Income tax000000000-1.76M
Net income-34.8M-25.5M-30.1M-27.0M-20.6M-17.8M-17.2M-11.4M-8.12M-6.37M
Earnings per share, basic-4.04-3.04-0.24-0.21-0.18-1.97-2.03-5.50-10.97-2.16
Earnings per share, diluted-4.04-3.04-0.24-0.21-0.18-1.97-2.03-5.50-10.97-2.16

Balance sheet

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Cash and equivalents41.3M71.1M88.5M110.9M136.4M39.6M12.6M10.4M7.22M3.03M
Short-term investments55.0K55.0K
Receivables-1.43M743.0K1.07M634.9K739.7K518.1K358.3K194.3K
Inventory1.49M5.25M2.60M1.92M972.3K619.8K305.9K0
Current assets45.6M74.5M92.2M118.2M141.2M42.8M14.3M11.5M7.90M3.25M
Property, plant and equipment20.0K21.0K34.4K54.5K11.5K55.1K
Goodwill00
Total assets47.6M76.4M96.3M123.5M141.3M42.8M14.5M11.7M8.16M4.14M
Accounts payable4.29M679.0K806.0K2.96M1.72M1.59M293.2K353.3K334.9K254.3K
Current liabilities8.26M4.97M5.24M5.57M3.13M15.7M1.32M2.92M1.23M1.05M
Long-term debt00
Total debt18.1K50.5K
Total liabilities8.26M4.97M5.24M5.57M3.13M15.7M1.33M2.92M1.23M1.05M
Shareholders' equity39.4M71.5M91.0M118.0M138.1M27.2M13.2M8.81M6.94M3.10M
Shares outstanding8.61M8.61M125.3M126.6M126.6M47.5M9.13M5.85M2.65M3.79M

Cash flow

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Cash from operations-29.8M-21.0M-20.9M-20.8M-16.5M-11.6M-9.13M-8.96M-6.59M-5.37M
Capital spending-23.0K-19.0K-14.0K-27.0K-9.00K-9.00K-7.63K-110.9K-110.9K-9.21K
Free cash flow-29.8M-21.0M-21.0M-20.8M-16.5M-11.6M-9.14M-9.07M-6.59M-5.38M
Cash from investing-23.0K-19.0K-14.0K-4.73M-9.00K-9.00K-7.63K-110.9K-110.9K-9.21K
Cash from financing03.67M-1.48M0113.3M38.6M11.3M12.3M10.8M4.70M
Dividends paid-4.50M00
Share buybacks0-1.48M0-5739.61M11.3M12.3M10.0M4.70M
Change in cash-29.8M-17.4M-22.4M-25.5M96.8M27.0M2.20M3.22M4.19M-687.9K